ADP-ribosyltransferases (ADPRTs) form an interesting class of enyzmes with well-established roles as potent bacterial toxins and metabolic regulators. ADPRTs catalyze the transfer of the ADP-ribose moiety from NAD + onto specific substrates including proteins. ADP-ribosylation usually inactivates the function of the target. ADPRTs have become adapted to function in extra-and intracellular settings. Regulation of ADPRT activity can be mediated by ligand binding to associated regulatory domains, proteolytic cleavage, disulphide bond reduction, and association with other proteins. Crystallisation has revealed a conserved core set of elements that define an unusual minimal scaffold of the catalytic domain with remarkably plastic sequence requirements-only a single glutamic acid residue critical to catalytic activity is invariant. These inherent properties of ADPRTs suggest that the ADPRT catalytic fold is an attractive, malleable subject for protein design.
ADP-ribosyltransferases catalyze ADP-ribosylation of targets
ADP-ribosyltransferases (ADPRTs) catalyze the transfer of the ADP-ribose moiety from bnicotinamide adenine dinucleotide (NAD + ) onto substrates including proteins, small molecular weight substances, and water, while releasing the nicotinamide moiety ( Fig. 1) (Aktories, 1991; Haag and Koch-Nolte, 1997) . The ADPRTcatalysed reaction is also designated ADP-ribosylation. Some ADPRTs are promiscuous with respect to substrate specificity, e.g. several arginine-specific ADPRTs including Pseudomonas aeruginosa exoenyzme S and murine ART2 can ADP-ribosylate several distinct target proteins as well as simple guanidino compounds (Koch-Nolte et al., 1996a,b; Radke et al., 1999) . Other AD-PRTs show exquisite specificity for a single target. For example, the only known substrate for the Clostridium botulinum C2 toxin and Salmonella typhimurium SpvB is actin, while that for diphtheria toxin and pseudomonas exotoxin A is elongation factor 2 (Aktories et al., 1986; Tezcan-Merdol et al., 2000; Wilson and Collier, 1992) .
ADP-ribosylation of proteins
In case of protein substrates, ADPRT catalysed protein ADP-ribosylation is akin to protein kinase-catalyzed protein phosphorylation. Like phosphorylation, ADP-ribosylation is a modification, which profoundly affects protein function. Diphtheria toxin-mediated ADP-ribosylation of elongation factor 2 blocks protein synthesis while cholera toxin-mediated ADP-ribosylation of the alpha subunit of the adenylate cyclase regulating G-protein leads to chronic activation of adenylate cyclase (Aktories, 1991) . Like phosphorylation, ADP-ribosylation is targeted towards specific amino acid residues. Subclasses of ADPRTs specific for arginine, cysteine, asparagine, glutamic acid, and diphthamide have been characterised. Like phosphorylation, ADP-ribosylation is potentially reversible. A distinct family of enzymes, ADP-ribosyl-protein glycohydrolases, can remove the ADP-ribose moiety from target proteins (Moss et al., 1992) , similar to the removal of phosphates from proteins by protein phosphatases. In both cases, removal of the chemical group can restore native protein function. Similar to the autophosphorylation exhibited by some protein kinases, some ADPRTs can auto-ADP-ribosylate themselves.
ADP-ribosylation of small molecules
A number of ADPRTs have been shown to ADP-ribosylate small molecules. As mentioned above, exoenzyme S and ART2 can ADP-ribosylate L-arginine in target proteins as well as free L-arginine and simple guanidino compounds. Some ADPRTs including PARP and tankyrase catalyze ADP-ribosylation of ADP-ribose itself, resulting in the formation of long, branched polymers of ADP-ribose (Oliver et al., 1999; Smith et al., 1998) . Recently, a bacterial ADPRT capable of ADP-ribosylating and thereby inactivating the antibiotic rifampin was discovered (Quan et al., 1999) . Moreover, a family of enzymes has been described which can transfer ADP-ribose from NAD + to a phosphate group in RNA (Spinelli et al., 1999) . A number of ADPRTs can also utilise This results in transfer of the ADP-ribose unit from NAD onto the target (ADP-ribosylation), while nicotinamide is released. Most commonly, the nucleophile resides in the side chain of a specific amino acid in a specific protein. ADPRTs specific for arginine, asparagine, glutamic acid, cysteine, and diphthamide (modified histidine) have been characterised by molecular cloning. Some ADPRTs can also ADP-ribosylate small molecular weight targets, e.g. the arginine-analogue agmatine or even water. The latter appears as NAD-glycohydrolase (NADase) activity.
H 2 O as acceptor for ADP-ribosylation, resulting in the glycohydrolysis of NAD + to nicotinamide and ADP-ribose.
Regulation of ADPRT-activity
In the course of evolution, ADPRT catalytic domains have become associated with diverse regulatory domains (Bazan and Koch-Nolte, 1997) . Some ADPRTs exhibit constitutive activity, others require proteolytic cleavage, reduction of a disulphide bond, or association with other proteins for activation. For example, diphtheria toxin is made as an inactive multidomain precursor protein (Wilson and Collier, 1992) . The receptor-binding domain determines host cell specificity and the translocation domain mediates passage thrflough the cell membrane. Proteolytic cleavage unleashes the catalytic domain and reduction of a disulphide bond activates enzyme activity. The activity of mammalian nuclear poly(ADP-ribosyl)transferases PARP1 and PARP2 is regulated by binding of DNA to a linked regulatory domain (Ame et al., 1999; Oliver et al., 1999) .
ADPRTs function in many different cellular compartments
ADP-ribosyltransferase has become well adapted to function in different cellular compartments. Mammalian ART1 and ART2 ADP-ribosylate cell membrane proteins on the extracellular leaflet of the plasma membrane, PARP1 and PARP2 ADPribosylate numerous nuclear proteins, and vault PARP ADP-ribosylates components of large cytoplasmic multiprotein complexes (Ame et al., 1999; Kickhoefer et al., 1999; Liu et al., 1999) . Many secretory bacterial ADPRTs ADP-ribosylate cytoplasmic target proteins in animal cells (Aktories, 1991; Wilson and Collier, 1992) .
Topology of the catalytic core of ADPRTs
The crystal structures of six bacterial toxin ADPRTs (see Note added in Proof) and of chicken PARP reveal a common topology of the catalytic domain (Allured et al., 1985; Bell and Eisenberg, 1996; Choe et al., 1992; Han et al., 1999; Ruf et al., 1998; Sixma et al., 1991; Stein et al., 1994; Zhang et al., 1995) . A conserved core set of six b-strands defines a minimal scaffold with remarkably plastic sequence requirements-only a single glutamic acid residue (E in b5) is invariant (Fig. 2) (Bazan and Koch-Nolte, 1997; Domenighini and Rappuoli, 1996; Koch-Nolte et al., 1996a,b) . The importance of this residue for catalytic activity was demonstrated originally by site directed mutagenesis in diphtheria toxin (Carrol and Collier, 1984) and has hence been confirmed in all other ADPRTs thus examined (Bazan and Koch-Nolte, 1997; Domenighini and Rappuoli, 1996) . Two other amino acid residues stabilise the active site and are also important for catalytic activity. These are histidine and tyrosine (H in b1, Y in b2) in diphtheria toxin (DT), pseudomonas exotoxin A (ETA) and PARP1, but arginine and serine (R in b1 and S in b2) in pertussis toxin (PT), cholera toxin (CT), E. coli heat labile enterotoxin (LT), and Bacillus insecticidal toxin VIP2 (Fig. 2) (Bazan and KochNolte, 1997; Domenighini and Rappuoli, 1996) .
Residues governing ADPRT target specificity
The conserved topology of the active site crevice indicates that modern ADPRTs diverged from a primordial ADPRT, yielding a family of enzymes with a conserved NAD-binding fold but diverse target specificities for ADP-ribosylation (Bazan and Koch-Nolte, 1997; Domenighini and Rappuoli, 1996) . The residues governing target-specificity have not yet been defined for any of the known ARTs. The exposed, nonconserved loops, which cradle the scissile glycosidic bond between ADP-ribose and nicotinamide lie in a position that faces the incoming target. These loops are highlighted in yellow, orange, and blue in the 3D structure of VIP2 in Fig. 3 . Strikingly, all known arginine-specific ADPRTs contain a glutamic acid residue at the end of the loop preceeding b5 (two residues upstream of the catalytic glutamic acid) (Fig. 2B, Fig. 3) . Mutation of this residue to glutamine has been shown to convert arginine-specific ADPRT activity into NAD-glycohydrolase activity in case of Clostridium botulinum C2 toxin, Clostridium perfringens iota toxin, Pseudomonas exoenyzme S, and rat ART2 (Barth et al., 1998; Hara et al., 1996; Karsten et al., 1997; Nagahama et al., 2000; Radke et al., 1999) . PARP contains a large insertion relative to other ADPRTs preceding b5 and this region has been implicated in binding the ADP-ribose polymer target (Ruf et al., 1998) .
Designer ADPRTs
With the three-dimensional structures of known ADPRTs as a guide, it should be possible to imitate nature and to alter the target specificity of ADPRTs by mutagenesis. Transforming existing ADPRTs into one another by site directed mutagenesis and grafting of specificity loops should be relatively straight forward with more closely related family members, but poses a greater challenge for more distant relatives. The fruit of such endeavours will be a better understanding of the structure/function relationship of ADPRT target specificity. With insight into the molecular basis of ADPRT target specificity it may be even possible one day to redirect ADPRTs from known to novel targets. Examples (Han et al., 1999) . (a) The six beta sheets forming the active site crevice are highlighted in yellow and are labelled as in Fig. 2 . The active-site residues arginine R349, serine S386, and glutamic acid E428 are depicted in red and correspond to the residues marked by asterisks in Fig.  2 . The only side chain shown is that of E428. The substrate NAD is depicted in cyan as a stick-model, the arrow points to the scissile glycosidic bond. (b) Space-fill model of VIP2 is depicted from the same angle as in (a). The active site residues R349, S386 and E428 are in red. The three loops that cradle the scissile glycosidic bond in NAD are highlighted in yellow, orange, and blue. The glutamic acid residue E426 in the loop preceding b5 which is characteristic of arginine-specific ADPRTs is depicted in green. The figure was compiled with the Rasmac program using the co-ordinates for Bacillus cereus insecticidal toxin VIP2 (PDB accession number 1QS2).
for practical applications that we envision include redirecting an ADPRT from fibroblast growth factor or tuftsin (Jones and Baird, 1997; Terashima et al., 1997) to other biologically important signalling peptides; from rifampin (Quan et al., 1999) to another antibiotic, or from one nucleotide-binding protein (EF2, actin, G-alpha, rho, ras) to another key metabolic regulator. Known ADPRTs have already proven their manifold usefulness as experimental tools in cell biology, e.g. to inhibit protein synthesis (ETA, DT), cytoskeletal functions (C2, C3), signal transduction (CT, PT), T-cell activation (ART1, ART2) (Aktories, 1991; Haag and Koch-Nolte, 1997; Koch-Nolte et al., 1996a,b; Liu et al., 1999; Wilson and Collier, 1992) . It is not hard to imagine that novel designer ADPRTs would be useful in these and other settings. The properties of natural ADPRTs-their plasticity in amino acid sequence requirements, their diverse target specificities, and their propensity to function in different environments-suggest that the ADPRT fold represents an attractive, malleable, and well suited subject for protein design.
Note added in proof
In their recent paper (Han et al., 2001 ) describing the 3D structure of the C3 exonenzyme from Clostridium botulinum, Tainer and coworkers also point out the importance of the bipartite loop connecting b4 and b5 for substrate recognition specificity (i.e. the loop marked by the arrow in Fig. 2 and highlighted in blue in Fig. 3 .
